📄 #PressRelease GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis 👉 https://lnkd.in/d8bHZnk 📄 #CommuniquédePresse GENFIT : Avis positif du Comité des médicaments à usage humain (CHMP) pour l’Iqirvo® (élafibranor) d’Ipsen dans la Cholangite Biliaire Primitive 👉 https://lnkd.in/e7Jaj5T6
GENFIT
Biotechnologie
Loos, Hauts-de-France 13 327 abonnés
Dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs.
À propos
GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Its capacity to develop high potential assets, from early-stages to late development and pre-commercialization stages, is illustrated through the successful 52-week readout of its Phase 3 trial (ELATIVE®) evaluating elafibranor in Primary Biliary Cholangitis (PBC). Today, GENFIT has a diversified R&D pipeline covering several therapeutic areas: five programs in acute on chronic liver failure (ACLF) are in clinical stages (Phase 2) and pre-clinical stages, including hepatic encephalopathy (HE), one of the main complications of ACLF; a Phase 2 clinical program targeting cholangiocarcinoma; and a preclinical program targeting urea cycle disorders (UCD) and organic acidemias (OA). GENFIT’s pipeline also includes a diagnostic franchise focused on Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis or NASH) and ammonia. GENFIT has facilities in Lille and Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s largest shareholders and holds 8% of the company’s share capital.
- Site web
-
http://www.genfit.com
Lien externe pour GENFIT
- Secteur
- Biotechnologie
- Taille de l’entreprise
- 51-200 employés
- Siège social
- Loos, Hauts-de-France
- Type
- Société cotée en bourse
- Fondée en
- 1999
- Domaines
- Drug Discovery, Drug Development, Liver disease, Clinical trial, ACLF, Cholestatic Diseases, HepaticEncephalopathy, Cholangiocarcinoma, Therapeutics, Diagnostics et UreaCycleDisorder
Lieux
-
Principal
Obtenir l’itinéraire
Parc Eurasanté
885, Avenue Eugène Avinée
59120 Loos, Hauts-de-France, FR
-
Obtenir l’itinéraire
1 Alewife Center
02140 Cambridge, Massachusetts, US
-
Obtenir l’itinéraire
8005 Zurich, CH
Employés chez GENFIT
Nouvelles
-
📣 Acute-on-Chronic Liver Failure (ACLF) is associated with potential for multiple organ failure. For an ACLF patient admitted into an intensive care unit, the odds of recovering and being discharged are approximately one out of two. To date, there is no approved treatment available and liver transplant remains the only cure. 👉 To learn more about how ACLF affects organs, watch our video here https://lnkd.in/epk7w377 #LiverFailure #MultipleOrganFailure #RareDisease #Cirrhosis
-
📢 Listen to Dean Hum, Chief Scientific Officer of GENFIT, talk about "How biotechs are revolutionizing acute on-chronic liver failure?" in the Beyond Biotech podcast - from Labiotech.eu 👉https://lnkd.in/eFk3_m8Q #ACLF #LiverDisease #Cirrhosis #RareDisease #OrganFailure #DrugDevelopment #Hepatology
How biotechs are revolutionizing acute on-chronic liver failure? - Beyond Biotech - the podcast from Labiotech
podcast.labiotech.eu
-
📣 Did you know that about 50% of patients with Acute-on-Chronic Liver Failure (#ACLF) in the #ICU do not recover? This stark statistic is just one factor motivating our teams to advance our pipeline of ACLF assets. 👉 Learn more about ACLF at https://lnkd.in/eXWyRg37 #LiverDisease #Cirrhosis #RareDisease #OrganFailure #DrugDevelopment #Hepatology
-
📣 We identify high-potential assets, capitalizing on our scientific, clinical and regulatory #expertise to investigate potential therapeutic solutions from early development stages to pre-commercial readiness. 👉 Learn more about our expertise at https://lnkd.in/erthPKXR #DrugDiscovery #Breakthroughs #LiverDisease #RareDisease #DrugDevelopment #DataScience
-
-
🎤 Pascal Prigent, Directeur Général, a participé à une interview de Laurent Grassin pour Le Journal des Biotechs. L'occasion de revenir sur l'approbation accélérée par la FDA d'#Iqirvo® (#élafibranor) dans la #PBC ; notre stratégie dans l'#ACLF ; et le potentiel de notre outil de diagnostic #NIS2 ® pour détecter la #MASH « à risque ». Merci pour cet échange. 👉 Retrouvez l'interview ici : https://lnkd.in/eHP3TAz6 #JournalDesBiotechs #Biotech #DrugDevelopment
-
-
📣 Our unique pipeline of five assets in development for Acute-on-Chronic Liver Failure (#ACLF) is based on differentiated mechanisms of action leveraging complementary pathways to achieve the best possible outcomes for patients. . 👉 Learn more about ACLF at https://lnkd.in/eXWyRg37 #LiverDisease #Cirrhosis #RareDisease #OrganFailure #LiverTransplant #DrugDevelopment
-
📣 Acute-on-Chronic Liver Failure (#ACLF) is a life-threatening condition with high short term mortality which represents a huge unmet medical need. Liver and transplant expert and researcher Dr. Jennifer Lai of the University of California, San Francisco, explains the need and what’s at stake. 👉 Learn more about ACLF at https://lnkd.in/eXWyRg37 #ACLF #LiverDisease #Cirrhosis #RareDisease #OrganFailure #LiverTransplant #AASLD
-
📢 Retrouvez l'interview de Pascal Prigent dans les Eco121. 👉 https://lnkd.in/e_AhZT8y
Genfit : L'Elafibranor officiellement commercialisé aux Etats-Unis. La biotech lilloise est la première en France à avoir réussi à porter une molécule de la phase préclinique jusqu'au marché américain, l'Elafibranor, contre la Cholangite Biliaire Primitive (PBC). Avec des retombées sonnantes et trébuchantes. Un article à découvrir sur le site d'Eco121 (lien en commentaire). GENFIT Pascal Prigent
-
-
📄 #PressRelease GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2 ® as Key Tool for Detecting At-Risk MASH 👉 https://lnkd.in/d8bHZnk 📄 #CommuniquéDePresse GENFIT : Les nouvelles recommandations de pratique clinique de l'EASL-EASD-EASO pour la MASLD incluent NIS2 ® comme outil-clé pour la détection de la MASH à risque 👉 https://lnkd.in/e7Jaj5T6
-
Pages similaires
Parcourir les offres d’emploi
Financement
GENFIT
7 rounds en tout
Voir plus d’informations sur Crunchbase
Dernier round
Capital après introduction en Bourse
Lien Crunchbase externe pour la dernière levée de fonds
49 319 916,00 $US